CancerDrs

Lung Cancer clinical trials in South Carolina

19 actively recruiting lung cancer trials at 18 sites across South Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Ralph H Johnson VA Medical Center — Charleston, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Cancer Institute — Greenville, South Carolina
  • Lexington Medical Center — West Columbia, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in South Carolina:
  • Medical University of South Carolina /ID# 251383 — Charleston, South Carolina
  • St Francis Cancer Center /ID# 243596 — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).

Sponsor: Taiho Oncology, Inc.
NCT ID: NCT07128199
Sites in South Carolina:
  • Gibbs Cancer Center and Research Institute Spartanburg — Spartanburg, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Ralph H Johnson VA Medical Center — Charleston, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed,…

Sponsor: CatalYm GmbH
NCT ID: NCT07098988
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multi-site study which will evaluate the safety, efficacy, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.

Sponsor: BioNTech SE
NCT ID: NCT06750185
Sites in South Carolina:
  • MUSC Hollings Cancer Center — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Phase 2 Study of Fingolimod in Lung Cancers

This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a…

Sponsor: Medical University of South Carolina
NCT ID: NCT06424067
Sites in South Carolina:
  • Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer

Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT06179069
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Recruiting Academic/Other

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …

Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
View on ClinicalTrials.gov →
Recruiting Industry

GEMINI-NSCLC: NSCLC Biomarker Study

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and di…

Sponsor: Tempus AI
NCT ID: NCT05236114
Sites in South Carolina:
  • The Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Recruiting Industry

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-c…

Sponsor: Freenome Holdings Inc.
NCT ID: NCT06122077
Sites in South Carolina:
  • Medical University of South Carolina (MUSC) — Charleston, South Carolina
  • McLeod Health — Florence, South Carolina
View on ClinicalTrials.gov →
Recruiting Industry

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…

Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in South Carolina:
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
  • Carolina Blood and Cancer Care Associates — Rock Hill, South Carolina
View on ClinicalTrials.gov →
NA Recruiting Federal

Prediction Augmented Screening Initiative

Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, …

Sponsor: VA Office of Research and Development
NCT ID: NCT06538636
Sites in South Carolina:
  • Ralph H. Johnson VA Medical Center, Charleston, SC — Charleston, South Carolina
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Health Education Approach to Lung Screening

Evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (LCS), defined as undergoing a low dose computed tomography (LDCT)

Sponsor: Virginia Commonwealth University
NCT ID: NCT06070870
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Protocol for Patients Living With Metastatic Lung Cancer

In this pilot randomized controlled trial, patients with metastatic non-small cell lung cancer and at least mild distress (N=80) will be randomized to receive LiveWell, an adapted Dialectical Behavioral Therapy (DBT) Skills Training protoc…

Sponsor: Medical University of South Carolina
NCT ID: NCT07177846
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19